Table 2.
Parameter | Value (%RSE, 95% CI) | Interindividual variability, % (%RSE, 95% CI) |
---|---|---|
Pharmacokinetic parameters | ||
N (subjects/PK observations) | 280/4573 | |
Clearance (L/d)a | 867 (10.2%, 727–1064) | 27.1 (15.1%, 22.0–31.0) |
ϴ Post menstrual age EC50a (weeks) | 96 (15.4%, 73–130) | – |
Volume of central compartment (L) | 592 (10.1%, 484–717) | 32.8 (56.3%, 11.8–48.5) |
Intercompartmental clearance 1 (L/d) | 511 (12.4%, 401–645) | – |
Volume of peripheral compartment 1 (L) | 7240 (8.2%, 6210–8440) | – |
Intercompartmental clearance 2 (L/d) | 671 (16.8%, 461–934) | – |
Volume of peripheral compartment 2 (L) | 1060 (18.2%, 731–1510) | – |
Absorption transit time (d)b | 0.045 (9.1%, 0.034–0.048) | 43.2 (42.2%, 22.4–60.1) |
ϴ Capillary to venous conversionc | 0.922 | – |
Proportional error | 44.6% (1.7%, 43.0%–46.0%) | – |
Relative bioavailability (F)b | 1 | |
ϴ Weight for age z-scored | 0.113 (18.9%, 0.061–0.137) | – |
ϴ Self-administered DPd | 0.397 (7.8%, 0.344–0.465) | – |
ϴ Between occasion variability | 66.9% (5.9%, 62.3%–71.3%) | |
Pharmacodynamic parameters | ||
N (subjects/observations) | 280/326 | |
Baseline hazard/1000 (per day)e | 0.402 (17.2%, 0.268–0.536) | 69.6 (66.1, 43.3–146) |
Season adjustment | ||
ϴ Transmission period 2015 | 1.29 (33.9%, 0.65–2.40) | – |
ϴ Transmission period 2016 | 5.20 (16.1%, 3.92–7.09) | |
ϴ Transmission period 2017 | 7.83 (16.7%, 5.75–10.96) | |
ϴ PPQ EC50 (ng/mL) | 6.00 (14.4%, 4.25–7.58) | – |
ϴ PPQ γ | 3.13 (24.3%, 1.96–4.89) |
Confidence intervals obtained by bootstrap (n = 1000).
aCL = ϴCL **.
bPre-specified absorption compartments.
cln([PPQ]capillary) = ϴ slope*ln([PPQ]venous).
dF = 1* ϴSelf-administered DP *(1 + ϴWAZ*(WAZ−(−0.5)))*eϴ Between occasion variability, WAZ weight for age z-score.
eSurvival function: ϴBaseline/1000* ϴTransmission period*.